Dr Hamilton on HRQOL Differences With Gilteritinib vs Placebo in Post-Transplant FLT3-ITD+ AML

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

Related Keywords

Betty Hamilton ,Marrow Transplant Clinical Trials Network ,Department Of Hematology ,Medical Oncology ,Cleveland Clinic ,Functional Assessment ,Cancer Therapy ,Bone Marrow Transplant ,Transplantation And Cellular Therapy Meetings ,Onclive Tv ,Hematologic Malignancies ,